Literature DB >> 11063819

Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis.

K Selmaj1, C Kowal, A Walczak, J Nowicka, C S Raine.   

Abstract

Vaccination with naked DNA represents a therapeutic strategy currently under consideration in multiple sclerosis (MS). In this study, we tested the potential therapeutic effect of vaccination with a naked DNA construct encoding proteolipid protein (pRc/CMV-PLP) upon the outcome of subsequent sensitization for experimental autoimmune encephalomyelitis (EAE) actively-induced in SJL mice with PLP139-151 peptide in adjuvant. Intramuscular vaccination with the naked DNA pRc/CMV-PLP construct led to PLP expression in local muscle tissue that persisted for about 8 weeks. Early sensitization for EAE (4 weeks after DNA vaccination) caused recipient mice to develop a severe, exacerbated form of disease (in comparison to control mice), while late sensitization (>10 weeks) resulted in a milder, ameliorated form. In the groups sensitized <10 weeks post-DNA vaccination with pRc/CMV-PLP induction of a Th1-type cytokine response was noted. In contrast, sensitization >10 weeks post-DNA vaccination led to peripheral tolerance as evidenced by a decrease in T cell proliferation and cytotoxic T cell response, no Th2 response, and no increase in apoptosis. These data are novel in that they demonstrate a differential effect of DNA vaccination and have important implications for its use as a mechanism to enhance or modulate immune reactivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063819     DOI: 10.1016/s0165-5728(00)00329-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

Review 1.  Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).

Authors:  Cris S Constantinescu; Nasr Farooqi; Kate O'Brien; Bruno Gran
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 2.  Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression.

Authors:  Hussein Baharlooi; Amir Hossein Mansourabadi; Moein Minbashi Moeini; Leila Mohamed Khosroshahi; Maryam Azimi
Journal:  Cell Mol Neurobiol       Date:  2021-10-25       Impact factor: 4.231

Review 3.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

5.  Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells.

Authors:  Phyllis B Silver; Rajeev K Agarwal; Shao-Bo Su; Isabelle Suffia; Rafael S Grajewski; Dror Luger; Chi-Chao Chan; Rashid M Mahdi; John M Nickerson; Rachel R Caspi
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

6.  Proteomic strategies in multiple sclerosis and its animal models.

Authors:  Stella Elkabes; Hong Li
Journal:  Proteomics Clin Appl       Date:  2007-10-16       Impact factor: 3.494

Review 7.  Emerging immunopharmacological targets in multiple sclerosis.

Authors:  Mojtaba Farjam; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2015-09-14       Impact factor: 3.181

Review 8.  Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.

Authors:  Cody D Moorman; Sue J Sohn; Hyewon Phee
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.